[go: up one dir, main page]

WO2025144221A1 - Complément alimentaire fonctionnel contenant des extraits de noisette enrichis en composants de noisette anticancéreux - Google Patents

Complément alimentaire fonctionnel contenant des extraits de noisette enrichis en composants de noisette anticancéreux Download PDF

Info

Publication number
WO2025144221A1
WO2025144221A1 PCT/TR2024/050814 TR2024050814W WO2025144221A1 WO 2025144221 A1 WO2025144221 A1 WO 2025144221A1 TR 2024050814 W TR2024050814 W TR 2024050814W WO 2025144221 A1 WO2025144221 A1 WO 2025144221A1
Authority
WO
WIPO (PCT)
Prior art keywords
hazelnut
dietary supplement
value
range
shells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/TR2024/050814
Other languages
English (en)
Inventor
Sule ARI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Micronut Biyoteknoloji AS
Original Assignee
Micronut Biyoteknoloji AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Micronut Biyoteknoloji AS filed Critical Micronut Biyoteknoloji AS
Publication of WO2025144221A1 publication Critical patent/WO2025144221A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L25/00—Food consisting mainly of nutmeat or seeds; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/10—Preparation or pretreatment of starting material
    • A61K2236/11—Preparation or pretreatment of starting material involving culturing conditions, e.g. cultivation in the dark or under defined water stress

Definitions

  • the invention relates to a functional dietary supplement and contains at least one of the group of the kernel, shell, or cell powder of hazelnuts having anticancer, nutritive, and flavoring properties as active ingredients, and hazelnut anticancer components.
  • Dietary supplements are products that are generally obtained from plant sources and contain various components in pure or mixture form. People use dietary supplements to be protected against and treat various chronic diseases, especially cancer, to help maintain and improve general health, or to take anti-aging measures.
  • Hazelnut contains a very high amount of tocopherols and tocotrienols (vitamin E). It also contains various flavonoids and phenolic acids (ferulic acid, caffeic acid, etc.). With these compounds they contain, hazelnuts will be able to serve as a dietary component with antioxidant properties for users.
  • Hazelnut as is known in the art, is a food component with high nutritional value. It contains about 600 to 700 calories of energy, protein at a value of 14 to 20 grams, carbohydrates at a value of 50 to 60 grams, and fiber at a value of 8 to 20 grams. Also, hazelnuts contain B vitamins and minerals. In this aspect, hazelnuts have high nutritional value for users owing to these nutritional values they contain.
  • hazelnut is a food component that fights free radicals with the compounds it contains, it has a structure that can reduce cellular damage and prevent oxidative stress. With this property, hazelnuts can be used as an anti-aging food component for users.
  • the inventors of the present invention aim to introduce a dietary supplement for the relevant technical field that effectively contains hazelnut anticancer components. For this, a functional dietary supplement enriched with anticancer components within hazelnuts is obtained.
  • the inventors of the present invention aim to introduce a functional dietary supplement containing hazelnuts with high nutritional values. For this, it introduces a functional dietary supplement containing enriched hazelnut extracts.
  • the inventors of the present invention aim to introduce a functional dietary supplement containing nuts with high aroma and flavor.
  • the dietary supplement of the invention contains the relevant parts of hazelnut as the main active ingredient.
  • the inventors of the present invention aim to obtain the beneficial chemical compounds and nutritional values of hazelnuts in the most effective way and to include them in dietary supplements.
  • the dietary supplement can be contained in capsules or tablets, in powder form, in liquid form, in chocolate or bars, in granules.
  • the scope of protection of the invention is not limited to the final product form of the dietary supplement.
  • the most preferred product form for the subject of the invention is the tablet or capsule form. Accordingly, the dietary supplement obtained in the invention has a configuration to be placed in capsules or tablets.
  • the components in the dietary supplement of the invention can be in powder or liquid form. However, this is optional, and with the methods known in the art, those in powder form can be converted into liquid, and liquid components into powder.
  • the scope of protection of the invention is not limited to the solid or liquid form of the components in the dietary supplement.
  • the dietary supplement of the invention has a hazelnut-containing composition. Accordingly, the dietary supplement contains hazelnut kernel (i.e. fruit) as a component. Hazelnut kernels are primarily used to give aroma and flavor to the dietary supplement. In addition, hazelnut kernels, as is known in the art, have very high nutritional value and compounds that provide antioxidant properties.
  • the dietary supplement of the invention contains the shell of hazelnuts as a component.
  • Hazelnuts as is known, have hard brown or green shells.
  • paclitaxel and its derivatives (10-deacetyl baccatin III, baccatin III, cephalomannine) has been detected in said hazelnut shells (regardless of color).
  • paclitaxel an alkaloid from the diterpene class, has a mechanism of action and broad-spectrum anti-neoplastic properties. It blocks mitosis by supporting the polymerization of a and p-tubulin heterodimers that form microtubules in the G2 phase during the cell cycle.
  • Hazelnut leaves similar to hazelnut shells, are first collected, then cleaned, and then ground.
  • the reason for applying production process steps in this way is to ensure that it is cleaned of microorganisms and that it remains homogeneously in the final product in the targeted sizes.
  • Cleaning processes are carried out with water and/or ozonated water. Subsequently, it is subjected to drying processes for grinding processes. The reason for this is that it is aimed to have a brittle structure for grinding processes. For this, a value between 60 to 75 °C is preferred, especially where the active compounds in the hazelnut shell/leaves are not damaged. After this process, it is ensured that the hazelnut leaves subjected to grinding process are ground to specified targets.
  • the dietary supplement of this invention contains hazelnut leaves that can pass through sieves with pore values of 2 mm or less as a component. The reason for these values is that it is aimed to obtain a homogeneous dietary supplement.
  • the dietary supplement of the invention contains hazelnut cell powder as a component.
  • hazelnut cell powder means the final components obtained as a result of suspension culturing processes.
  • Hazelnut cell suspension samples obtained after culturing processes are collected.
  • the obtained hazelnut cell suspension cultures are taken into tubes in a preferred embodiment.
  • Centrifugation processes are applied to the tubes containing cultures. This centrifugation process is preferably carried out at a value in the range of 7500 to 10000 rpm for a period of 10 to 20 minutes. Centrifugation processes are carried out to obtain the precipitate to be processed from the solution.
  • the precipitate obtained after this process is turned into powder so that it can be included in the dietary supplement.
  • the powderization process is carried out by lyophilization process in a preferred embodiment.
  • the lyophilization process is carried out for at least 24 hours, preferably at a temperature in the range of -50 to -60 °C.
  • Hazelnut cell powder contains paclitaxel and its derivatives. It is also a part rich in terms of antioxidant content. Adding hazelnut cell powder as a component to the dietary supplement will allow the functionality of the final product to increase.
  • the dietary supplement of the invention contains the extract containing hazelnut anticancer components.
  • Hazelnut cell powder is used as a raw material to obtain extracts containing hazelnut anticancer components.
  • the hazelnut cell powder obtained as characterized by the previous process step of the invention is subjected to washing processes with dichloromethane in a preferred embodiment. Instead of the dichloromethane mentioned here, other compounds that can perform the same function can also be used for washing processes.
  • incubation processes are performed in an ultrasonication device on the hazelnut cell powders subjected to washing processes.
  • Other devices that provide the same function can also be used for incubation processes.
  • the incubation process is preferably 1 hour. The supernatant obtained as a result of the incubation process is collected and transferred to the tubes for the next process steps.
  • a mixture is obtained by adding methanol:water solution to the tubes containing the supernatant.
  • methanol-water is a solution containing methanol at a value between 80% and 90% by weight in a preferred embodiment.
  • n-hexane is added to this mixture in a preferred embodiment.
  • the n-hexane:methanol-water ratio in this mixture is a value in the range of 8:1 to 4:1.
  • the obtained mixture is subjected to centrifugation processes to obtain new supernatant liquid to be used in the next processes. This centrifugation process is preferably carried out at a value in the range of 7500 to 10000 rpm for a period of 10 to 20 minutes.
  • the supernatant liquid obtained is evaluated as an extract and subjected to washing processes with dichloromethane.
  • the extract obtained is subjected to removal processes, preferably at 40 °C under vacuum in order to remove the methanol it may contain.
  • the dietary supplement of the invention contains extract containing hazelnut anticancer components as a component.
  • the extract is in liquid form, as can be expected.
  • the dietary supplement contains an extract containing hazelnut anticancer components at a value in the range of 1 % to 10% (v/w) of the extract. While determining the ratio of hazelnut anticancer compounds in the product, the amounts known to be effective on cancer cells in scientific studies were taken into account. Concentrations below this amount may reduce the effectiveness of the compounds, while concentrations above it are likely to cause side effects.
  • the dietary supplement of the invention contains the hazelnut extract containing anticancer components, as well as hazelnut cell powder as a component.
  • Hazelnut cell powder obtained from hazelnut cell cultures is at a value in the range of 1 % to 10% (w/w) in the dietary supplement. While determining the ratio of hazelnut cell powder obtained from hazelnut cell cultures in the product, the amounts known to be effective on cancer cells in scientific studies were taken into account. In the studies conducted, using the concentrations of obtaining hazelnut anticancer compounds, the value of the amount to reach bioactive properties was calculated. Concentrations below this amount may reduce the effectiveness of the compounds, while concentrations above it are likely to cause side effects.
  • the dietary supplement of the invention contains the extract containing hazelnut anticancer components and hazelnut cell powder as a component, in addition, it contains at least one of the group of powdered hazelnut shells, hazelnut kernels, and hazelnut leaf as a component.
  • the dietary supplement contains ground hazelnut kernels, hazelnut shells and hazelnut leaf components all together.
  • the total presence of these components is at a value in the range of 80% to 98% (w/w).
  • the dietary supplement of the invention contains hazelnut shells in the range of 20% to 50% (w/w), hazelnut kernels in the range of 20% to 50% (w/w), and hazelnut leaves in the range of 10% to 30% (w/w).
  • hazelnut parts in the product and their ratios have been determined by taking into account that the hazelnut product to be produced contains sufficient amounts of compounds for its physical structure, consistency, taste, and bioactivity. It has been determined that the ratio of phenolic compounds obtained from the shell, which constitutes 42% of the total biomass of hazelnuts by weight, varies between 0.5-1 .5% by weight.
  • hazelnut kernel is the most commercially valuable part and is known to contain protein, fatty acids, vitamins and phenolic compounds in abundance. Further, it is the part that gives the hazelnut its unique taste. In order for the dietary supplement to have the envisaged biological activity, hazelnut kernels are used at a value in the range of 20% to 50% (w/w).
  • the product must be present in certain ratios to ensure the taste of the product. It is known that there is a higher ratio of bioactive compounds (phenolics) in hazelnut leaves than in hazelnut kernels. However, due to their seasonal formation, the product contains hazelnut leaves at a value in the range of 10% to 30% (w/w). Thus, the enriched content envisaged in the product is ensured.
  • bioactive compounds phenolics
  • Functional dietary supplements/supplements to be obtained with the hazelnut shell/hazelnut kernel/leaf components and hazelnut cell powder/FAB to be added can be added to many foods, and in addition to the nutritional properties of foods, their qualities in terms of preventive health, especially for cancer, can be increased.
  • the product/products obtained can be used in the future to increase the nutritional and functionality values of hazelnut-based vegetable milks from plant dairy products.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Botany (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne un complément alimentaire fonctionnel contenant un groupe d'amande, de coque et/ou de poudre cellulaire de noisettes ayant des propriétés anticancéreuses, nutritives et aromatiques en tant que principes actifs, et des composants de noisette anticancéreux.
PCT/TR2024/050814 2023-12-29 2024-07-12 Complément alimentaire fonctionnel contenant des extraits de noisette enrichis en composants de noisette anticancéreux Pending WO2025144221A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2023/019682A TR2023019682A1 (tr) 2023-12-29 2023-12-29 Findik anti̇kanser bi̇leşenleri̇ i̇le zengi̇nleşti̇ri̇lmi̇ş findik ekstreleri̇ i̇çeren bi̇r fonksi̇yonel gida takvi̇yesi̇
TR2023/019682 2023-12-29

Publications (1)

Publication Number Publication Date
WO2025144221A1 true WO2025144221A1 (fr) 2025-07-03

Family

ID=96218561

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2024/050814 Pending WO2025144221A1 (fr) 2023-12-29 2024-07-12 Complément alimentaire fonctionnel contenant des extraits de noisette enrichis en composants de noisette anticancéreux

Country Status (2)

Country Link
TR (1) TR2023019682A1 (fr)
WO (1) WO2025144221A1 (fr)

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANGELA HOFFMAN, FEREIDOON SHAHIDI: "Paclitaxel and other taxanes in hazelnut", JOURNAL OF FUNCTIONAL FOODS, ELSEVIER BV, NL, vol. 1, no. 1, 11 October 2008 (2008-10-11), NL , pages 33 - 37, XP055292471, ISSN: 1756-4646, DOI: 10.1016/j.jff.2008.09.004 *
ESPOSITO TIZIANA, SANSONE FRANCESCA, FRANCESCHELLI SILVIA, DEL GAUDIO PASQUALE, PICERNO PATRIZIA, AQUINO RITA, MENCHERINI TERESA: "Hazelnut (Corylus avellana L.) Shells Extract: Phenolic Composition, Antioxidant Effect and Cytotoxic Activity on Human Cancer Cell Lines", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, MOLECULAR DIVERSITY PRESERVATION INTERNATIONAL (MDPI), BASEL, CH, vol. 18, no. 2, 13 February 2017 (2017-02-13), Basel, CH , pages 392, XP093333339, ISSN: 1422-0067, DOI: 10.3390/ijms18020392 *
OTTAGGIO L, BESTOSO F, ARMIROTTI A, BALBI A, DAMONTE G, MAZZEI M, SANCANDI M, MIELE M.: "Taxanes from Shells and Leaves of Corylus avellana.", JOURNAL OF NATURAL PRODUCTS, AMERICAN CHEMICAL SOCIETY, US, vol. 71, no. 1, 1 January 2008 (2008-01-01), US , pages 58 - 60, XP002752079, ISSN: 0163-3864, DOI: 10.1021/np0704046 *

Also Published As

Publication number Publication date
TR2023019682A1 (tr) 2025-07-21

Similar Documents

Publication Publication Date Title
US10709149B2 (en) Preparation of coffee fruit extracts and powders
Charalampia et al. From pomegranate processing by-products to innovative value added functional ingredients and bio-based products with several applications in food sector
JP2008504030A (ja) 緑茶製剤およびその製造方法
El Sheikh et al. Nutritional value, cytotoxicity, anti-carcinogenic and beverage evaluation of roasted date pits
KR101440468B1 (ko) 홍삼 분말을 이용한 홍삼 에너지바
Barreira et al. Bioactive compounds of chestnut (Castanea sativa Mill.)
US20060277887A1 (en) Method for processing organic plant matter into dry powder, oil and juice products
Sheikh et al. Plum wastes and by-products: Chemistry, processing, and utilization
KR102249707B1 (ko) 초고압 처리를 이용한 인삼열매의 가공방법
WO2025144221A1 (fr) Complément alimentaire fonctionnel contenant des extraits de noisette enrichis en composants de noisette anticancéreux
KR101030693B1 (ko) 조릿대 잎 추출물의 제조방법 및 그 추출물을 이용한 음료
KR100903689B1 (ko) 프로폴리스의 기능성이 함유된 쌀 및 이의 제조방법
KR20210081298A (ko) 항비만 조성물 및 이의 제조 방법
KR101402224B1 (ko) 우뭇가사리 추출물을 포함하는 기능성 식품
KR20120124038A (ko) 아조엔이 함유된 마늘 오일의 제조방법
KR102022677B1 (ko) 천연 저염소스의 제조 방법
KR101492472B1 (ko) 효소 및 저온 가공기법을 이용한 잣 기름의 제조방법 및 이로부터 제조된 잣 기름을 함유하는 항비만용 조성물
KR20140108237A (ko) 저칼로리 함량을 가지는 항산화 성분, 이를 얻기 위한 방법 및 이의 용도
KR101671490B1 (ko) 미네랄 강화 견과류 및 이의 제조방법
US20180360062A1 (en) Prune-based nutrient-rich materials and related processes
RU2825781C1 (ru) Пищевой функциональный продукт
KR20150074683A (ko) 꾸찌뽕 분말화 제조방법
RU2776790C1 (ru) Способ производства растворимых экстрактов напитков из растительного сырья
KR20210020388A (ko) 고추 분말 제조방법 및 그 제조방법에 의해 제조된 고추 분말
KR102555338B1 (ko) 호박씨 오일을 함유하는 식품 조성물.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24913926

Country of ref document: EP

Kind code of ref document: A1